SCHEMBL6945557

SCHEMBL6945557

ON=C1CCN(CCN2CCCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
KMT2A Q03164 2/20 0.44
CYP2D6 P10635 1/20 0.44
CHRNA7 P36544 1/20 0.43
SIGMAR1 Q99720 1/20 0.39
LMNA P02545 1/20 0.38
HRH3 Q9Y5N1 2/20 0.37
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 1/20 0.34
NPC1 O15118 1/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
PRMT8 Q9NR22 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8111365 1.00 TSHR (0.44) TSHRCASP1KMT2ACYP2D6CHRNA7
SCHEMBL6942305 0.98 TSHR (0.48) TSHRCASP1KMT2ACYP2D6CHRNA7
SCHEMBL8107495 0.98 TSHR (0.48) TSHRCASP1KMT2ACYP2D6CHRNA7
SCHEMBL6939825 0.90 HRH3 (0.48) TSHRCASP1KMT2ACYP2D6CHRNA7
SCHEMBL6941674 0.83 ALDH1A1 (0.47) KMT2ACHRNA7SIGMAR1ALDH1A1MAPT
SCHEMBL6949290 0.83 CHRNA7 (0.45) TSHRCASP1KMT2ACYP2D6CHRNA7
SCHEMBL8108818 0.83 ALDH1A1 (0.47) KMT2ACHRNA7SIGMAR1ALDH1A1MAPT
SCHEMBL8108846 0.80 CHRNA7 (0.47) TSHRCASP1KMT2ACYP2D6CHRNA7
SCHEMBL6945248 0.80 CHRNA7 (0.47) TSHRCASP1KMT2ACYP2D6CHRNA7
SCHEMBL6944691 0.78 CHRNA7 (0.41) TSHRCASP1KMT2ACHRNA7SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed
EP-1056744-A1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043675-A1 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 TSHR 4411/4885CASP1 289/4885KMT2A 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.